Jordan Park

Jordan Park

Healthcare & Biotech Analyst

Healthcare and biotech analyst focused on pharma pipelines, medtech adoption curves, and reimbursement dynamics. Former clinical research coordinator and later equity research analyst. Writes thesis-driven pieces that connect clinical catalysts, competitive landscapes, and valuation scenarios.

Articles 769

Jan 1, 2026 Finance

Chris Christie Raises Legal and Ethical Concerns Over Sports Prediction Markets

Former Governor Foresees Supreme Court Involvement as Unregulated Platforms Challenge State Laws

Chris Christie, former Governor of New Jersey and current strategic advisor to the American Gaming Association, has voiced alarm over the unregulated ...

Mastering Stock Trading Order Execution: How to Optimize Timing and Minimize Market Impact for Better Results
Jan 1, 2026 Education

Mastering Stock Trading Order Execution: How to Optimize Timing and Minimize Market Impact for Better Results

A comprehensive guide for beginner and intermediate traders to understand and improve order execution timing, reduce trading costs, and manage risks effectively

Order execution—the process of buying or selling a stock—is a critical factor that directly influences trading performance, yet many traders under...

Trump Critiques George Clooney's Political Stance and Dual Citizenship
Jan 1, 2026 Business News

Trump Critiques George Clooney's Political Stance and Dual Citizenship

Former President Challenges Actor's Political Influence and French Nationality Acquisition

Former President Donald Trump has publicly criticized George Clooney, focusing on the actor's political endorsements, his commentary on President Bide...

Zohran Mamdani’s Historic Inauguration: Sworn in Using a Centuries-Old Quran
Jan 1, 2026 News & Politics

Zohran Mamdani’s Historic Inauguration: Sworn in Using a Centuries-Old Quran

New York City's first Muslim, South Asian, and African-born mayor's oath symbolizes the city’s diverse heritage

Zohran Mamdani, taking office as New York City's mayor, marked a series of historic firsts by being the city's first Muslim, South Asian, and African-...

Jan 1, 2026 Trade Ideas

Micron at an Inflection: Trade the AI-Driven Memory Rally

The memory supplier play now reads like Nvidia in 2016—strong demand, tight supply, and cash-rich fundamentals. Tactical long with clear rules.

Micron's latest quarter shows a meaningful revenue and profit inflection driven by AI/data-center memory demand. Balance sheet strength, massive opera...

Trade Idea Long
Mastering Stock Trading Seasonality: How to Identify and Leverage Recurring Market Patterns for Smarter Timing and Risk Management
Jan 1, 2026 Education

Mastering Stock Trading Seasonality: How to Identify and Leverage Recurring Market Patterns for Smarter Timing and Risk Management

For beginner and intermediate traders seeking to understand seasonal trends in stock markets and incorporate them into disciplined trading strategies

Seasonality refers to recurring price patterns or tendencies linked to specific times during the year, month, or trading cycle. This comprehensive gui...

New Year's Day 2026: Retail Operations Continue Amid Government and Banking Closures
Jan 1, 2026 News & Politics

New Year's Day 2026: Retail Operations Continue Amid Government and Banking Closures

A comprehensive guide to which services and stores operate during the holiday

As the nation observes New Year's Day in 2026, government entities and financial institutions will remain closed, while most major retailers will cont...

Jan 1, 2026 Trade Ideas

Rigel Pharmaceuticals: Building a 2026 Playbook — Buy on Discipline, Size for Volatility

Revenue inflection, cash strength, and a clearer commercial path make RIGL a tactical long — trade plan included.

Rigel (RIGL) has moved from a cash-burning developer to a profitable, cash-rich company in 2025 thanks to accelerating revenues and expanding gross ma...

Trade Idea Long
Jan 1, 2026 Trade Ideas

Why Viking Could Be a Speculative Play on the Oral GLP-1 Frenzy

Cash-rich balance sheet + heavy R&D = takeover optionality in a market that prizes oral metabolic assets

Viking Therapeutics (VKTX) is a paradox: no revenues, heavy R&D (Q3 2025 R&D $89.95M), and a balance sheet with large current assets ($738.7M). The ma...

Trade Idea Long
Inflation-Driven Risks Signal Potential Market Challenges in 2026
Dec 31, 2025 Business News

Inflation-Driven Risks Signal Potential Market Challenges in 2026

Elevated inflation and rising bond yields pose significant threats to market stability, overshadowing AI-related concerns

While the stock market has displayed remarkable resilience in recent years, looming inflationary pressures and corresponding increases in bond yields ...